ClinicalTrials.gg
TerminatedNCT04475549Updated Aug 29, 2024Results posted

Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)

A Phase 2 interventional study of IW-6463 Tablets in MELAS, sponsored by Tisento Therapeutics. Terminated at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-29.

Sponsored by Tisento Therapeutics · Phase 2, Interventional, and Treatment

Why this study was terminated
Study terminated due to enrollment challenges.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies in MELAS Syndrome with a site in United States — 6 open to participants now, 6 under way, 1 of them phase 3. MELAS Syndrome · United States.

Enrollment
15th of 15
8 · median 27
Started
2020
with 1 other
Phase 2
5 of 21
none open now
Registered
13th of 21
by date
Lead sponsor
3 of 21
Tisento Therapeutics

Among the 21 studies in MELAS Syndrome with a site in United States, this one is the 15th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2020, is one of 5 in phase 2, and was the 13th registered.

MELAS Syndrome

37 studies on the registry are indexed under MELAS Syndrome; 8 are open to participants now.

Browse MELAS Syndrome studies →

Open to participants now

6 of the 21 studies in MELAS Syndrome with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 MELAS Syndrome studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in MELAS Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a single-arm study to evaluate safety and tolerability of oral IW-6463 in adults diagnosed with MELAS.

Read the detailed description

IW-6463 tablets will be orally administered once-daily (QD) for up to 29 days

03

Conditions studied

  • MELAS

Keywords

  • mitochondrial disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Prior genetic confirmation of a known mitochondrial disease mutation
  2. Neurological features of MELAS (can be based on medical history)
  3. Elevated plasma lactate levels at Screening Visit (≥1.0 mmol/L)
  4. Women of must have a negative pregnancy test prior to randomization and must agree to use protocol-specified from the Screening Visit through 90 days after the final dose of study drug.
  5. Male participants must be surgically sterile by vasectomy (conducted ≥60 days before the Screening Visit or confirmed via sperm analysis) or must agree to use protocol-specified contraception and agree to refrain from sperm donation from the Screening Visit through 90 days after the final dose of study drug.
  6. Other inclusion criteria per protocol

Exclusion criteria

Exclusion Criteria:

  1. Positive pregnancy test at Screening or on Day 1
  2. Hypotension defined as systolic blood pressure (BP) ≤90 mmHg or diastolic BP ≤60 mmHg at Screening or predose at Day 1
  3. Hypertension defined as systolic BP >160 mmHg or diastolic BP >100 mmHg, at Screening or predose at Day 1
  4. Uncontrolled diabetes
  5. Severe gastrointestinal dysmotility as determined by the investigator that may impact compliance and/or oral drug administration, absorption and exposure.
  6. Unable to fast for 3-4 hours after a meal
  7. Unable or unwilling to adhere to the study schedule, lifestyle restrictions, assessment requirements or, in the clinical judgment of the investigator, is otherwise not suitable for study participation.
  8. Current or past history of cardiomyopathy and/or cardiac conduction abnormality
  9. Used any nicotine-containing products (eg, cigarettes, e-cigarettes, vape pens, cigars) within 1 month of enrollment
  10. Other exclusion criteria per protocol
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    IW-6463

    Open-label IW-6463 15 mg once daily (QD), with possibility to dose reduce to 10 mg.

    Drug: IW-6463 Tablets

Interventions

  • IW-6463 tablets administered orally (daily)

    Also known as: CY6463, zagociguat

06

What researchers measure

Primary outcomes

  1. Number of Participants With Study Drug Dose Reductions or Discontinuations Due to ≥ 1 Treatment Emergent Adverse Event (TEAE)

    A TEAE is defined as an adverse event (AE) with an onset that occurs between the first dose of study drug and the end of study period. AEs are defined as an untoward medical occurrence that does not necessarily have a causal relationship with study drug treatment.

    Time frame: From first dose date to Day 43 (±4)

  2. Number of Participants Who Experienced ≥1 AE, TEAE, Serious AE (SAE), or TEAE of Special Interest (AESI)

    AEs are defined as an untoward medical occurrence that does not necessarily have a causal relationship with study drug treatment. A TEAE is defined as an AE with an onset that occurs from the first dose of study drug up until the end of study period. An SAE is an AE that fulfills 1 or more of the following: results in death; is immediately life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; results in a congenital abnormality or birth defect; is an important medical event that may jeopardize the participant or may require medical intervention to prevent 1 of the outcomes listed above. Events were categorized as mild, moderate, or severe and as related or unrelated to study drug. AESIs include bleeding events, symptomatic hypotensive events and/or tachycardia, dizziness, syncope, and TEAEs related to change of neurobehaviors (ie, suicidality or euphoria).

    Time frame: From first dose date to Day 43 (±4)

07

Results

Posted Nov 15, 2023

Participant flow

Participant flow — Overall Study
MilestoneIW-6463
Started8
Completed8
Not completed0

Outcome measures

PrimaryNumber of Participants With Study Drug Dose Reductions or Discontinuations Due to ≥ 1 Treatment Emergent Adverse Event (TEAE)

A TEAE is defined as an adverse event (AE) with an onset that occurs between the first dose of study drug and the end of study period. AEs are defined as an untoward medical occurrence that does not necessarily have a causal relationship with study drug treatment.

Time frame:
From first dose date to Day 43 (±4)
Reported as:
Count of participants · Participants
Number of Participants With Study Drug Dose Reductions or Discontinuations Due to ≥ 1 Treatment Emergent Adverse Event (TEAE)
ParticipantsIW-6463
Dose reduction due to TEAE1
Study drug discontinuation due to TEAE0
PrimaryNumber of Participants Who Experienced ≥1 AE, TEAE, Serious AE (SAE), or TEAE of Special Interest (AESI)

AEs are defined as an untoward medical occurrence that does not necessarily have a causal relationship with study drug treatment. A TEAE is defined as an AE with an onset that occurs from the first dose of study drug up until the end of study period. An SAE is an AE that fulfills 1 or more of the following: results in death; is immediately life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; results in a congenital abnormality or birth defect; is an important medical event that may jeopardize the participant or may require medical intervention to prevent 1 of the outcomes listed above. Events were categorized as mild, moderate, or severe and as related or unrelated to study drug. AESIs include bleeding events, symptomatic hypotensive events and/or tachycardia, dizziness, syncope, and TEAEs related to change of neurobehaviors (ie, suicidality or euphoria).

Time frame:
From first dose date to Day 43 (±4)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced ≥1 AE, TEAE, Serious AE (SAE), or TEAE of Special Interest (AESI)
ParticipantsIW-6463
Any AE8
Any pretreatment AE1
Any TEAE8
Any severe TEAE0
Any study drug-related TEAE4
Any SAE0
Any TEAE leading to study drug discontinuation0
Any TEAE leading to death0
Any treatment-emergent AESI4

Adverse events

Collected over From signing of informed consent (all-cause mortality) or first dose date (adverse events) to Day 43 (±4).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IW-64630/8 (0%)0/8 (0%)8/8 (100%)
Most frequent other events
Showing 10 of 37
Most frequent other events
EventIW-6463
HeadacheNervous system disorders3/8
Oedema peripheralGeneral disorders2/8
Cerebrovascular accidentNervous system disorders1/8
Disturbance in attentionNervous system disorders1/8
DizzinessNervous system disorders1/8
DysarthriaNervous system disorders1/8
HypoaesthesiaNervous system disorders1/8
Abdominal pain upperGastrointestinal disorders1/8
ConstipationGastrointestinal disorders1/8
DiarrhoeaGastrointestinal disorders1/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)IW-6463
Mean32.8 ± 12.41
Sex: Female, Male
Sex: Female, Male(Participants)IW-6463
Female5
Male3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IW-6463
Hispanic or Latino0
Not Hispanic or Latino8
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IW-6463
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White6
More than one race0
Unknown or Not Reported1
08

Study locations

5 sites
  • Children's National Hospital of DC
    Washington, District of Columbia 20010, United States
  • Johns Hopkins University
    Baltimore, Maryland 21205, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Columbia University
    New York, New York 10032, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Jan 2022, 14 months.

Results were first posted in Nov 2023, 1 year 9 months after primary completion. A results delay was requested in Jan 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2020
First posted
Jul 17, 2020
StartActual
Nov 13, 2020
Primary completionActual
Jan 23, 2022
CompletionActual
Jan 23, 2022
Results delay requested
Jan 20, 2023
Results first posted
Nov 15, 2023
Last update
Aug 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04475549
Lead sponsor
Tisento Therapeutics
Responsible party
Sponsor
First posted
Jul 17, 2020
Start date
Nov 13, 2020
Primary completion
Jan 23, 2022
Completion
Jan 23, 2022
Results posted
Nov 15, 2023
Last update
Aug 29, 2024

Study contacts

Chad Glasser, PharmD
study director · Cyclerion Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zagociguat

Start the discussion